Tianjin Chase Sun Pharmaceutical Co Ltd - Asset Resilience Ratio
Tianjin Chase Sun Pharmaceutical Co Ltd (300026) has an Asset Resilience Ratio of -0.89% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 300026 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2023)
This chart shows how Tianjin Chase Sun Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Tianjin Chase Sun Pharmaceutical Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Tianjin Chase Sun Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300026 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥-105.72 Million | -0.89% |
| Total Liquid Assets | CN¥-105.72 Million | -0.89% |
Asset Resilience Insights
- Limited Liquidity: Tianjin Chase Sun Pharmaceutical Co Ltd maintains only -0.89% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Tianjin Chase Sun Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tianjin Chase Sun Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for Tianjin Chase Sun Pharmaceutical Co Ltd (2006–2023)
The table below shows the annual Asset Resilience Ratio data for Tianjin Chase Sun Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.89% | CN¥-105.72 Million ≈ $-15.47 Million |
CN¥11.84 Billion ≈ $1.73 Billion |
+0.36pp |
| 2022-12-31 | -1.25% | CN¥-158.00 Million ≈ $-23.12 Million |
CN¥12.63 Billion ≈ $1.85 Billion |
+0.33pp |
| 2021-12-31 | -1.58% | CN¥-183.67 Million ≈ $-26.88 Million |
CN¥11.61 Billion ≈ $1.70 Billion |
+0.20pp |
| 2020-12-31 | -1.78% | CN¥-181.52 Million ≈ $-26.56 Million |
CN¥10.18 Billion ≈ $1.49 Billion |
-1.09pp |
| 2019-12-31 | -0.69% | CN¥-58.31 Million ≈ $-8.53 Million |
CN¥8.43 Billion ≈ $1.23 Billion |
-0.28pp |
| 2018-12-31 | -0.41% | CN¥-30.99 Million ≈ $-4.53 Million |
CN¥7.48 Billion ≈ $1.10 Billion |
-0.53pp |
| 2006-12-31 | 0.12% | CN¥124.36K ≈ $18.20K |
CN¥105.62 Million ≈ $15.46 Million |
-- |
About Tianjin Chase Sun Pharmaceutical Co Ltd
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company provides Chinese medicine formula granules, finished drugs, raw materials, medical devices and excipients, medical and health services, as well as smart supply chain for pharmaceuticals and medical devices. It serves th… Read more